Keith Stuart
Lahey Hospital & Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Keith Stuart as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04844970 · Anamorelin Study for Advanced Pancreatic CancerLahey Clinic · terminated · Metastatic Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:48 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- Activity of sunitinib in patients with advanced neuroendocrine tumors.J Clin Oncol · 2008485 citationsRCR 12.8
- Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.J Clin Oncol · 2006411 citationsRCR 11.2
- Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.J Clin Oncol · 2006319 citationsRCR 7.1
- 229 citationsRCR 5.5
- Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.J Clin Oncol · 2012218 citationsRCR 6.9
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Hepatology · 2016213 citationsRCR 8.8
- 200 citationsRCR 4.6
- A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.Clin Cancer Res · 2013137 citationsRCR 3.7
- Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy.AJR Am J Roentgenol · 2002133 citationsRCR 4.1
- 103 citationsRCR 3.5